Management of stage IE primary XXXX .

@entity1 @entity6595 @entity1074 @entity1072 @entity158
From 1975 to 1991, stage IE @entity6595 was diagnosed or treated in 40 @entity1 at our institution. Thirty-five evaluable @entity1 were the subject of this analysis (median age, 63 years). All histologic specimens were reviewed and classified according to the working formulation. Immunohistochemical stains were performed in 33 of 35 cases. The following histologic subtypes were identified: 26 @entity1 had diffuse large cell, 2 had diffuse mixed cell, and 7 had mucosa-associated @entity1072 ( @entity1072 with features of @entity1074 ). Of the 35 @entity1 , 30 (86%) underwent laparotomy, with subtotal or total gastrectomy performed in 29. After gastrectomy, 17 @entity1 had radiation therapy, 3 had chemotherapy, 2 had radiation plus chemotherapy, and 7 had no further treatment. Five @entity1 were diagnosed with endoscopic biopsy and had radiation therapy, chemotherapy, or both without further surgical treatment. The median follow-up period was 69.2 months. The commonest presenting symptom was @entity158 . The 5-year disease-free survival was 90% for the entire group and 88% for the 28 @entity1 with working formulation intermediate histology. For @entity1 with @entity1074 , the 5-year disease-free survival was 100%. The prognosis for @entity1 with stage IE working formulation intermediate-histology @entity6595 is good and for those with stage IE @entity1074 , excellent.
